Research
Hormonal
Cidea promotes lipid storage by inhibiting AMPK stability and activity, thereby suppressing fatty acid oxidation and energy expenditure in brown adipose tissue.
Cidea acts as a brake on your body's ability to burn fat by degrading AMPK, a key enzyme that triggers fat burning. Removing this brake (as seen in knockout mice) allows AMPK to function, leading to higher fat oxidation. This suggests that drugs which inhibit Cidea could potentially boost metabolic rate by restoring AMPK activity.
GoodSupportsHIGH confidence
Cidea can specifically interact with AMPK-beta subunit and promote the ubiquitination-mediated proteosome degradation of AMPK complex... increased AMPK levels and its enzymatic activity lead to significantly increased fatty acid beta-oxidation in Cidea-null adipocytes.
Why this rating
Supported by molecular biology studies showing interaction with AMPK and degradation pathways.
Source
CIDE proteins and metabolic disorders
Jingyi Gong et al. · Current Opinion in Lipidology · 2009
DOI 10.1097/mol.0b013e328328d0bb
narrative_reviewCited 167×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Genetic deficiency or knockdown of CIDE family proteins (Cidea, Cideb, Fsp27) induces a lean phenotype, increases energy expenditure, and confers resistance to diet-induced obesity and insulin resistance.Good
- Fsp27 (Cidec) deficiency in white adipose tissue induces a 'browning' effect, characterized by increased mitochondrial activity, smaller lipid droplets, and improved insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →